Synonym
7-((1R,2R,3R)-3-hydroxy-2-((S)-3-hydroxyoctyl)-5-oxocyclopentyl)heptanoic acid
IUPAC/Chemical Name
7-((1R,2R,3R)-3-hydroxy-2-((S)-3-hydroxyoctyl)-5-oxocyclopentyl)heptanoic acid
InChi Key
DPOINJQWXDTOSF-DODZYUBVSA-N
InChi Code
InChI=1S/C20H36O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h15-17,19,21,23H,2-14H2,1H3,(H,24,25)/t15-,16+,17+,19+/m0/s1
SMILES Code
CCCCC[C@H](O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
356.50
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Fitscha P, Rauscha F, Rogatti W, Peskar BA, O'Grady J, Sinzinger H.
13,14-dihydro-PGE1, an in-vivo metabolite of PGE1, decreases mitotic activity
induced by corticosteroid administration. Eicosanoids. 1991;4(4):231-3. PMID:
1789999.
2: Ney P, Braun M, Szymanski C, Bruch L, Schrör K. Antiplatelet, antineutrophil
and vasodilating properties of 13,14-dihydro-PGE1 (PGE0)--an in vivo metabolite
of PGE1 in man. Eicosanoids. 1991;4(3):177-84. PMID: 1663381.
3: Leonhardt A, Schweer H, Wolf D, Seyberth HW. Formation of biologically active
13,14-dihydro-prostaglandin E1 during intravenous infusion of prostaglandin E1
in newborns with ductus arteriosus-dependent congenital heart disease. Br J Clin
Pharmacol. 1992 Mar;33(3):323-5. doi: 10.1111/j.1365-2125.1992.tb04044.x. PMID:
1576056; PMCID: PMC1381284.
4: Sinzinger H, Virgolini I, Li SR, Gerakakis A, Fitscha P, O'Grady J. Increase
in in vivo low-density lipoprotein (LDL) receptor binding after PGE1 and
13,14-dihydro-PGE1 treatment in rabbits. J Cardiovasc Pharmacol. 1993
Mar;21(3):503-6. doi: 10.1097/00005344-199303000-00023. PMID: 7681515.
5: Braun M, Ney P, Hohlfeld T, Szymanski C, Bruch L, Schrör K. Pharmakologie von
13,14-Dihydro-PGE1 im Vergleich zu PGE1 [The pharmacology of 13,14-dihydro-PGE1
in comparison with PGE1]. Vasa Suppl. 1991;33:337-8. German. PMID: 1788747.
